Patent: 9,717,649
✉ Email this page to a colleague
Summary for Patent: 9,717,649
Title: | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
Abstract: | The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, Prolia.RTM. (denosumab), Xgeva.RTM. (denosumab), Aranesp.RTM. (darbepoetin alfa), AMG-145, romosozumab (AMG-785), ganitumab (AMG-479), trebananib (AMG-386), brodalumab (AMG-827), and rilotumumab (AMG-102). |
Inventor(s): | Weeks; Wendell P. (Corning, NY), Schaut; Robert Anthony (Painted Post, NY), DeMartino; Steven Edward (Painted Post, NY), Peanasky; John Stephen (Big Flats, NY) |
Assignee: | Corning Incorporated (Corning, NY) |
Application Number: | 14/259,261 |
Patent Claims: | see list of patent claims |
Details for Patent 9,717,649
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Amgen, Inc. | ARANESP | darbepoetin alpha | Injection | 103951 | 09/17/2001 | ⤷ Try a Trial | 2039-02-26 |
Amgen, Inc. | ARANESP | darbepoetin alpha | Injection | 103951 | 07/19/2002 | ⤷ Try a Trial | 2039-02-26 |
Amgen, Inc. | ARANESP | darbepoetin alpha | Injection | 103951 | 12/17/2002 | ⤷ Try a Trial | 2039-02-26 |
Amgen, Inc. | ARANESP | darbepoetin alpha | Injection | 103951 | 12/12/2003 | ⤷ Try a Trial | 2039-02-26 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |